Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound

Next Previous
Trial Profile

Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Atherosclerosis; Low HDL cholesterol
  • Focus Therapeutic Use
  • Acronyms ASSURE; ASSURE-1
  • Sponsors Resverlogix Corporation

    • Most Recent Events

    • 28 Aug 2018 Results assessing the effect of Apabetalone on Attenuated Coronary Atherosclerotic Plaque, published in the American Journal of Cardiovascular Drugs
    • 17 Jul 2018 According to a Resverlogix Corporation media release, results fromt his trial will be preasented at Clinical Trials in Alzheimers Disease (CTAD) Asia and Alzheimers Association International Conference (AAIC)
    • 04 Apr 2018 Results (n=48) of post hoc analysis from SUSTAIN and ASSURE trials assessing the effects of pharmacologic epigenetic modulation on levels of ALP and kidney function via apabetalone published in the Kidney and Blood Pressure Research.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top